Keywords: USA, GlaxoSmithKline, Paxil, Law suits, Consultants fees
GlaxoSmithKline paid $1 billion in Paxil suits; reveals fees to US consultants
Article | 15 December 2009
GlaxoSmithKline, the world’s second-largest drugmaker, has paid nearly $1 billion to resolve law suits over Paxil (paroxetine) since it began selling the antidepressant in 1993, Bloomberg News reported, citing court records and people familiar with the cases.
That total does not include more than 600 claims that Paxil caused birth defects. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
